Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
Article excerpt
Highlighted: the sentence this signal was extracted from
Pfizer currently generates a higher volume of absolute revenue, while Bristol Myers Squibb displays a more consistent baseline without the recent negative fluctuations seen by the former. Over the last eight quarters, Pfizer experienced fluctuating quarter-over-quarter results with multiple periods of year-over-year contraction, whereas Bristol Myers Squibb maintained a steadier trajectory characterized by continuous year-over-year growth. Investors should watch whether Pfizer's recent return to positive year-over-year revenue growth stabilizes in upcoming quarters, or if the two companies see their absolute revenue gap continue to narrow. Motley Fool Issues Rare "Total Conviction" Buy Alert › Bristol Myers Squibb (NYSE:BMY) primarily generates revenue by developing and selling prescription medicines for oncology, immunology, and cardiovascular diseases. It recently received accelerated FDA approval for its multiple myeloma treatment Zenbexus, and it announced a $2.3 billion investment to build a new manufacturing campus in Texas. Pfizer (NYSE:PFE) primarily generates revenue by manufacturing and distributing a broad portfolio of prescription medicines and vaccines worldwide. It secured FDA approval for a Tukysa regimen to treat metastatic breast cancer, while it also received authorization for its updated seasonal COVID-19 vaccine for the upcoming season. Revenue here...
Keep reading with a free account
The rest of this article, and every signal for Bristol Myers Squibb, is in your free account.
